Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients;Badania polimorfizmów genów CYP1A1, CYP1B1 i CYP3A4 u chorych z rakiem piersi

Ginekologia Polska

Volumn 80, Issue 11, 2009, Pages 819-823

  Marta, Ociepa Zawal ^a   Błazej, Rubiś ^a   Violetta, Filas ^a   Jan, Breborowicz ^a   Trzeciak Wieslaw H ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; CYP1A1; CYP1B1; CYP3A4; Genetic; Polymorphisms

Indexed keywords

CYP3A4 PROTEIN, HUMAN; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; CYTOCHROME P450 1A1; CYTOCHROME P450 3A; UNSPECIFIC MONOOXYGENASE;

ADULT; AGE; AGED; ARTICLE; BREAST TUMOR; CAUCASIAN; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS;

EID: 77449116744     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tabor H, Risch N, Myers R. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet. 2002, 3, 391.
2. Crofts F, Taioli E, Trachman J, [et al.]. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994, 15, 2961-2963.
3. Chen C, Huang Y, Li Y, [et al.]. Cytochrome P450 1A1 (CYP1A1) T3801C and A2455G polymorphisms in breast cancer risk: a meta-analysis. J Hum Genet. 2007, 52, 423-435.
4. Masson L, Sharp L, Cotton S, [et al.]. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. Am J Epidemiol. 2005, 161, 901-915.
5. Okobia M, Bunker C, Zmuda J, [et al.]. Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women. Breast Cancer Res Treat. 2005, 94, 285-293.
6. Ambrosone C, Freudenheim J, Graham S, [et al.]. Cytochrome P4501A1 and glutathione Stransferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 1995, 55, 3483-3485.
7. Human Cytochrome P450 (CYP) Allele Nomenclature Committee http://www.imm.ki.se/CYPalleles/. 2004.
8. Bruning T, Abel, J, Koch B, [et al.]. Real-time PCR-analysis of the cytochrome P450 1B1 codon 432-poymorphism. Arch Toxicol. 1999, 73, 427-430.
9. Shimada T, Watanabe J, Kawajiri,K, [et al.]. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999, 20, 1607-1613.
10. Bailey L, Roodi N, Dupont W, [et al.]. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998, 58,50385041.
11. Han W, Kang D, Park I, [et al.]. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin Cancer Res. 2004, 10, 124130.
12. Roos P, Bolt H. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol. 2005, 1, 187-202.
13. Sata F, Sapone A, Elizondo G, [et al.]. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000, 67, 48-56.
14. Keshava C, McCanlies E, Weston A. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004, 160, 825-841.
15. Kadlubar F, Berkowitz G, Delongchamp R, [et al.]. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003, 12, 327-331.
16. Chu W, Fyles A, Sellers E, [et al.]. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis. 2007, 28, 2139-2142.
17. Kawajiri K, Watanabe J, Hayashi S. Identification of allelic variants of the human CYP1A1 gene. Methods Enzymol. 1996, 272, 226-232.
18. Lai J, Vesprini D, Chu W, [et al.]. CYP gene polymorphisms and early menarche. Mol Genet Metab. 2001, 74, 449-457.
19. Ando Y, Tateishi T, Sekido Y, [et al.]. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1999, 91, 1587-1590.
20. de Jong M, Nolte I, te Meerman G, [et al.]. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002, 39, 225-242.
21. Garte S, Gaspari L, Alexandrie A, [et al.]. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001, 10,1239-1248.
22. van Schaik R, de Wildt S, Brosens R, [et al.]. The CYP3A4*3 allele: is it really rare? Clin Chem. 2001, 47, 11041106.
23. Ball S, Scatina J, Kao J, [et al.]. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther. 1999, 66, 288-294.
24. Nerurkar P, Okinaka L, Aoki C, [et al.]. CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev. 2000, 9, 11191122.
25. Terry K, Titus-Ernstoff L, Garner E, [et al.]. Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2003, 12,187-190.
26. Listgarten J, Damaraju S, Poulin B, [et al.]. Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res. 2004, 10, 2725-2737.
27. De Vivo I, Hankinson S, Li L, [et al.]. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002. 11, 489-492.
28. DeMichele A, Aplenc R, Botbyl J, [et al.]. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol. 2005, 23, 5552-5559.
29. DeMichele A, Gimotty P, Botbyl J, [et al.]. In response to " Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort" . J Clin Oncol. 2007, 25, 56755677.
30. Long J, Cai Q, Shu X, [et al.]. Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet Genomics. 2007, 17,331-338.
31. Erdogan S, Ergin M, Tuncer I. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors. Neoplasma. 2003, 50, 326-330.
32. Swiatoniowski G, Dabrowska M, Klaniewski T, [et al.]. Erb-2 overexpression in breast cancer. Ginekol Pol. 2003, 74, 332-338.
33. Mark H, Aswad B, Bassily N, [et al.]. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization. Genet Med. 1999, 1, 98-103.
34. Torresan C, Oliveira M, Torrezan G, [et al.]. Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med. 2008, 8, 65-71.